Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 704.24

+1.6%

Nov 17 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Felix B who wrote (2359)	3/21/2018 6:39:55 PM
From: Miljenko Zuanic	Read Replies (1) of 3559

I think that siRNA GalNAc-conjugate approach from ALNY is good choice for liver targeted therapeutic, and that siRNA based silencing RNA molecule is also good choice for this target. One can question 50:50 deal (maybe REGN could get more), but that is their choice, and we should respect their best-efforts! finance.yahoo.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next